Consistent with this, anifrolumab, a therapeutic agent which inhibits the IFNAR receptor, and subsequently prevents the activation of Tyk1 and Jak2, was recently shown to have significant steroid-sparing effects in patients with active SLE in a successful phase 3 clinical trial (5). The gene discussed is JAK2; the disease is systemic lupus erythematosus.